Cognitive Effects of Bioavailable Curcumin (NCT07251985) | Clinical Trial Compass
WithdrawnPhase 2
Cognitive Effects of Bioavailable Curcumin
Stopped: Sponsor withdrew.
0Started 2026-04-01
Plain-language summary
An estimated 50% of older adults complain of memory changes that worsen as they age. Although numerous commercially available dietary supplements claim cognitive benefits, relatively few well-designed, longitudinal, placebo-controlled studies have rigorously evaluated their effects on cognitive performance.
In a previous double-blind, randomized, placebo-controlled, 18-month clinical trial in middle-aged and older non-demented adults, the investigators found that a bioavailable form of curcumin taken orally twice a day showed greater gains on specific measures of memory and attention relative to placebo. Although the investigators found significant between-group curcumin/placebo differences with moderate effect sizes, the sample size (n=40) was small. The present adequately powered, randomized, double-blind, placebo-controlled study will evaluate the effect of daily consumption of bioavailable curcumin on measurable changes in cognitive performance in non-demented middle-aged and older adults.
Who can participate
Age range50 Years – 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Presence of age-related memory complaints;
✓. Male or female aged 50 to 85 years of age at Visit 1.
✓. performance on MoCA test of \>= 18 (Milani et al, 2018)
✓. Ability to perform normal daily activities independently (which excludes a diagnosis of dementia).
✓. Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
✓. Agreement to participate in the entire study, which could last either 6 or 12 months depending on results of the interim analysis.
✓. Adequate visual and auditory acuity for cognitive testing.
✓. Screening laboratory tests that do not show significant medical problems that might interfere with study participation or impact cognitive test results.
. Presence of a condition or abnormality that in the opinion of the site Principal Investigator would compromise the safety of the patient or the quality of the data.
✕. Significant cerebrovascular disease or Alzheimer disease or any other dementia.
✕. Neurological or physical illnesses that can produce cognitive deterioration.
✕. History of myocardial infarction within the previous year or unstable cardiac disease.
✕. Uncontrolled hypertension (systolic BP \> 170 or diastolic BP \> 100); significant liver or pulmonary disease, or cancer;
✕. Current diagnosis of any major psychiatric disorder according to the DSM-IV TR criteria with a change in medication or clinical symptoms with the last 3 months prior to screening (APA, 2000).
✕. History of alcoholism or substance addiction in the last 15 years.